Compressed Gas Association

The Standard For Safety Since 1913

CGA M-21—2022

GUIDELINE FOR DETERMINING PHARMACOVIGILANCE REPORTING REQUIREMENTS IN NORTH AMERICA

SECOND EDITION

This document licensed for the sole use of the purchaser. It may not be shared with any other person or used after the expiration date without the express written permission of the CGA. Any unauthorized use, reproduction, distribution, or modification of this printed page will result in a $5,000 liquidated damages fee plus loss of access to CGA publications for one year for your company.

Documents
Document Sharing Hub
Full document details: CGA M-21-2022

Licensed for the sole use of the purchaser. See license agreement penalties for distribution.

PLEASE NOTE:

The information contained in this document was obtained from sources believed to be reliable and is based on technical information and experience currently available from members of the Compressed Gas Association, Inc. and others. However, the Association or its members, jointly or severally, make no guarantee of the results and assume no liability or responsibility in connection with the information or suggestions herein contained. Moreover, it should not be assumed that every acceptable commodity grade, test or safety procedure or method, precaution, equipment or device is contained within, or that abnormal or unusual circumstances may not warrant or suggest further requirements or additional procedure.

This document is subject to periodic review, and users are cautioned to obtain the latest edition. The Association invites comments and suggestions for consideration. In connection with such review, any such comments or suggestions will be fully reviewed by the Association after giving the party, upon request, a reasonable opportunity to be heard. Proposed changes may be submitted via the Internet at our web site, www.cganet.com.

This document should not be confused with federal, state, provincial, or municipal specifications or regulations; insurance requirements; or national safety codes. While the Association recommends reference to or use of this document by government agencies and others, this document is purely voluntary and not binding unless adopted by reference in regulations.

A listing of all publications, audiovisual programs, safety and technical bulletins, and safety posters is available via the Internet at our website at www.cganet.com. For more information contact CGA at Phone: 703-788-2700, ext. 799. E-mail: customerservice@cganet.com.

Work Item 24-56
Medical Gases Committee

NOTE—Technical changes from the previous edition are underlined.

SECOND EDITION: 2022
FIRST EDITION: 2017
© 2022 The Compressed Gas Association, Inc. All rights reserved.
All materials contained in this work are protected by United States and international copyright laws. No part of this work may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopying, recording, or any information storage and retrieval system without permission in writing from The Compressed Gas Association, Inc. All requests for permission to reproduce material from this work should be directed to The Compressed Gas Association, Inc., 8484 Westpark Drive, Suite 220, McLean, VA 22102. You may not alter or remove any trademark, copyright or other notice from this work.

Documents
Document Sharing Hub

Full document details: CGA M-21-2022

This document licensed for the sole use of the purchaser. It may not be shared with any other person or used after the expiration date without the express written permission of the CGA. Any unauthorized use, reproduction, distribution, or modification of this printed page will

Licensed for the sole use of the purchaser. See license agreement penalties for distribution.

Contents **Page**

1 Introduction 1

2 Scope 1

3 Definitions 1

4 U.S. and Canadian pharmacovigilance requirements 2

5 Vigilance evaluation 3
5.1 Awareness of a potential reportable event 3
5.2 Documentation of the report 3
5.3 Evaluation of the report 3

6 Reporting 4
6.1 United States 4
6.2 Canada 5

7 References 5

Table

Table 1—Explanation of the rationale applied to the decision on reportability 4

Documents
Document Sharing Hub

Full document details: CGA M-21-2022

This document licensed for the sole use of the purchaser. It may not be shared with any other person or used after the expiration date without the express written permission of the CGA. Any unauthorized use, reproduction, distribution, or modification of this printed page will